BreakBio Corp
BreakBio is dedicated to pioneering personalized cancer treatment through AI/ML and mass spectrometry technology. Their platform designs drugs specific to each patient's cancer, enabling treatment across all solid cancers at any stage. The company's mission is to develop therapies with curative intent for solid cancers of any type, aiming for breakthroughs in cancer care and FDA Breakthrough Therapy Designation.
Industries
Nr. of Employees
small (1-50)
Products
Personalized multi-epitope peptide cancer vaccine (IND-authorized)
A patient‑specific therapeutic vaccine composed of synthesized peptides selected from that patient's tumor sequencing and mass spectrometry data to induce T-cell responses against multiple tumor-restricted targets.
Personalized multi-epitope peptide cancer vaccine (IND-authorized)
A patient‑specific therapeutic vaccine composed of synthesized peptides selected from that patient's tumor sequencing and mass spectrometry data to induce T-cell responses against multiple tumor-restricted targets.
Services
Personalized neoantigen discovery and vaccine design
End-to-end service combining tumor/normal sequencing, mass spectrometry, per-patient AI/ML prioritization, and design of multi-epitope peptide vaccine formulations.
Personalized neoantigen discovery and vaccine design
End-to-end service combining tumor/normal sequencing, mass spectrometry, per-patient AI/ML prioritization, and design of multi-epitope peptide vaccine formulations.
Expertise Areas
- Personalized cancer vaccine development
- Neoantigen discovery and immunopeptidomics
- Immunogenomics and TCR repertoire analysis
- Cloud-based bioinformatics and workflow automation
Key Technologies
- Mass spectrometry (immunopeptidomics)
- Next-generation sequencing (DNA/RNA)
- AI/ML models for neoantigen prioritization
- Cloud computing (AWS)